Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Leo Pharma gets EC nod for psoriasis treatment Kyntheum
The approval allows to market Kyntheum in all 28 European Union (EU) member countries, as well as Iceland, Liechtenstein and Norway. Kyntheum is a new biologic medicine developed
The approval allows to market Kyntheum in all 28 European Union (EU) member countries, as well as Iceland, Liechtenstein and Norway. Kyntheum is a new biologic medicine developed
Dharmacon, which manufactures RNAi products, has a portfolio of gene editing products, particularly in CRISPR reagents and arrayed libraries. It had generated revenues of $36.7m in 2016 with an EBITDA of $5.4m.
The two companies have also entered into a license agreement which gives the global exclusive rights of BioMarin's DMD patent estate to Sarepta Therapeutics for $35m. Sarepta will
The approval was granted for Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) tablets, which is a single-tablet regimen to re-treat chronic HCV infection in adults. The approval
Evenity is an investigational bone-forming monoclonal antibody developed for the treatment of osteoporosis. The treatment is not yet approved by any regulatory authority. The decision has been taken
The company, dubbed Qrativ, will leverage on the medical expertise and clinical data of Mayo Clinic’s and on the AI-driven knowledge synthesis platform of nference. Initially, Qrativ will focus
Under the deal, Sanofi will secure $97.5m upfront payment, as well as up to $27.5m based on the achievement of certain regulatory and manufacturing-related milestones. Once the deal
The Kyprolis-based regimen yielded positive results by meeting the key secondary endpoint of overall survival (OS) in what was a second phase 3 trial dubbed as ASPIRE conducted
The company has received approval for Tremfya to treat adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is a
The CTL019 is an investigational chimeric antigen receptor T cell (CAR-T) therapy developed to treat patients with r/r B-cell ALL. The recommendation of ODAC was based on the